Open AccessExpression of programmed death-ligand 1 and programmed death-1 in patients with extramammary paget's disease
Author(s) -
Hiroyuki Goto,
Kazunari Sugita,
Osamu Yamamoto
Publication year - 2021
Publication title -
indian journal of dermatology/indian journal of dermatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.395
H-Index - 36
eISSN - 1998-3611
pISSN - 0019-5154
DOI - 10.4103/ijd.ijd_341_18
Subject(s) - medicine , extramammary paget's disease , immunohistochemistry , paget disease , pd l1 , disease , cancer , immune system , pathology , antibody , oncology , cancer research , immunology , immunotherapy
Extramammary Paget's disease (EMPD) is a rare skin cancer and sometimes has fatal prognosis. For progressive cases, therapeutic options are limited. In recent years, treatment with an anti-programmed death-1 (PD-1) antibody has improved the prognosis of various malignancies. In addition, correlations between PD-ligand 1 (PD-L1) expression in tumor cells and favorable responses to anti-PD-1 therapy have been reported for several cancers. There have been a few case series of analysis of PD-L1 expression in patients with EMPD.